Live Breaking News & Updates on Risto lammintausta

Stay informed with the latest breaking news from Risto lammintausta on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Risto lammintausta and stay connected to the pulse of your community

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies


(0)
Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women's health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo's therapeutic concept. The company is now planning the Phase 2 program including endometriosis patients in the US.
"The now completed Phase 1 program delivered an initial body of tolerability, safety and pharmacokinetic data. For chronic endometriosis treatment, tolerability and a lack of systemic estrogen deficiency-related side effects are of the utmost importance as we see current therapies struggling to be widely adopted due to their side effect profiles. A local effect on the target tissue with our intracrinology mechanism provides an opportunity for superior management of endometriosis," commented Risto Lammintausta, CEO of Forendo. "We are now looking forward to expanding our clinical development program into the US and potentially into complementary women's health indications, in addition to endometriosis. The upcoming Phase 2 program will transition the clinical evaluation of FOR-6219 into symptomatic patients and deepen our understanding of the drug's impact on the disease biology and endometriotic tissue."

Finland , Kostenloser-wertpapierhandel , Forendo-pharma , Caroline-rufo , Risto-lammintausta , Linkedin , Twitter , Karolinska-development , Novartis-venture-fund , Novartis , Novo-seeds , Vesalius-biocapital

FOR-6219 shows promise in Phase I endometriosis trial

FOR-6219 was found to be safe and well tolerated by healthy women and did not induce systemic oestrogen deficiency-related side effects.

Forendo-pharma , Risto-lammintausta , Chief-executive-officer , தலைமை-நிர்வாகி-அதிகாரி ,

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

Finland , Forendo-pharma , Caroline-rufo , Risto-lammintausta , Linkedin , Twitter , Karolinska-development , Novartis-venture-fund , Novartis , Novo-seeds , Vesalius-biocapital , Sunstone-life-science